Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Field Medical has developed the FieldForce Ablation System, a next-generation pulsed field ablation catheter platform. Early pilot studies—VCAS for ventricular tachycardia and PULSE for atrial fibrillation—have demonstrated promising acute results in first-in-human use. The system is designed to deliver rapid, focal cardiac ablation with high efficacy and minimal collateral damage. The company is preparing for pivotal trials and has received FDA Breakthrough Device Designation as well as inclusion in the FDA TAP Pilot Program.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Field Medical.